Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

21 evidence topics · 26 sources

Current treatment options and standard of care14 evidence topics · 11 sources
Place in treatment, anticipated use, and care setting1 evidence topic · 13 sources
Heterogeneity of treatment effect1 evidence topic · 1 source
Care management intervention strategies1 evidence topic · 1 source
Other product development or post-marketing obligations required by the FDA1 evidence topic · 1 source
Ongoing post-approval monitoring2 evidence topics · 2 sources
Expected outcomes of therapy1 evidence topic · 1 source